Sinopharm announces new board committee structure and director roles

Sinopharm Group Co. Ltd. has announced its board of directors and their respective roles and functions, along with the membership of its five board committees. The board includes seven non-executive directors, one executive director, and five independent non-executive directors. Zhao Bingxiang serves as chairman of the board, while Lian Wanyong holds the position of president and executive director.

The company operates with five board committees: Audit, Remuneration, Nomination, Strategy and Investment, and Legal and Compliance and Environmental, Social and Governance. Zhao Bingxiang chairs the Nomination and Strategy and Investment committees, and is a member of the Legal and Compliance and Environmental, Social and Governance Committee. Li Peiyu chairs the Remuneration Committee and is a member of the Audit and Strategy and Investment committees. Wu Tak Lung chairs the Audit Committee and is a member of the Remuneration and Nomination committees. Yu Weifeng chairs the Legal and Compliance and Environmental, Social and Governance Committee and is a member of the Remuneration and Nomination committees.

Several directors hold multiple committee memberships. For instance, Feng Rongli is a member of both the Remuneration and Nomination committees. Chen Yuqing and Wen Deyong are both members of the Strategy and Investment Committee. The announcement, dated November 6, 2025, from Shanghai, underscores Sinopharm Group Co. Ltd.'s structured governance.